NASDAQ:PTCT

Ptc Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy PTCT

*Your capital is at risk

$68.01

-7.51 (-9.94%)

At Close: Jul 31, 2026

PTC Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -63.08. In total, the insiders bought 511.32K and sold 202.71K PTCT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-63.08
● Buy	511.32K shares
● Sell	202.71K shares
57% Buy Activity Strong Negative Correlation
Buy Signal Low Confidence Jul 28, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -63.08. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 28, 2026 Buy	Common Stock	Sollie-zetlmayer Hege Elisabeth Director	Director	0 Value: $0
Jul 28, 2026 Buy	Stock Option (Right to Buy)	Sollie-zetlmayer Hege Elisabeth Director	Director	27 500 Value: $2.11M
Jul 28, 2026 Buy	Common Stock A-Award	Sollie-zetlmayer Hege Elisabeth Director	Director	4 000 Value: $301.6K
Jul 28, 2026 Buy	Common Stock A-Award	Sollie-zetlmayer Hege Elisabeth Director	Director	2 000 Value: $150.8K
Jul 28, 2026 Buy	Stock Option (Right to Buy) A-Award	Sollie-zetlmayer Hege Elisabeth Director	Director	3 475 Value: $262.0K
Jul 28, 2026 Buy	Stock Option (Right to Buy)	Sollie-zetlmayer Hege Elisabeth Director	Director	25 000 Value: $642.3K
Jul 28, 2026 Buy	Stock Option (Right to Buy) A-Award	Sollie-zetlmayer Hege Elisabeth Director	Director	1 738 Value: $131.0K
Jul 28, 2026 Buy	Stock Option (Right to Buy)	Sollie-zetlmayer Hege Elisabeth Director	Director	25 000 Value: $1.16M
Jul 28, 2026 Buy	Stock Option (Right to Buy)	Sollie-zetlmayer Hege Elisabeth Director	Director	11 250 Value: $443.5K
Jul 28, 2026 Buy	Stock Option (Right to Buy)	Sollie-zetlmayer Hege Elisabeth Director	Director	17 875 Value: $681.0K
Jul 28, 2026 Buy	Stock Option (Right to Buy)	Sollie-zetlmayer Hege Elisabeth Director	Director	33 250 Value: $2.21M
Jul 28, 2026 Buy	Stock Option (Right to Buy)	Sollie-zetlmayer Hege Elisabeth Director	Director	14 000 Value: $727.4K
Jul 14, 2026 Sell	Common Stock S-Sale	Gravier Pierre Chief Financial Officer	C-Suite Officer	3 494 Value: $280.7K
Jul 09, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Smith Mary L. Director	Director	5 834 Value: $250.6K
Jul 09, 2026 Sell	Common Stock S-Sale	Almstead Neil Gregory Chief Technical Ops Officer	Officer	2 464 Value: $222.4K
Jul 09, 2026 Buy	Common Stock M-Exempt	Smith Mary L. Director	Director	10 000 Value: $429.5K
Jul 09, 2026 Buy	Common Stock M-Exempt	Smith Mary L. Director	Director	5 834 Value: $250.6K
Jul 09, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Almstead Neil Gregory Chief Technical Ops Officer	Officer	2 464 Value: $114.7K
Jul 09, 2026 Buy	Common Stock M-Exempt	Almstead Neil Gregory Chief Technical Ops Officer	Officer	2 464 Value: $114.7K
Jul 09, 2026 Sell	Common Stock S-Sale	Smith Mary L. Director	Director	5 834 Value: $525.1K
Jul 07, 2026 Sell	Common Stock S-Sale	Almstead Neil Gregory Chief Technical Ops Officer	Officer	9 288 Value: $830.7K
Jul 07, 2026 Sell	Common Stock S-Sale	Almstead Neil Gregory Chief Technical Ops Officer	Officer	11 369 Value: $1.01M
Jul 07, 2026 Buy	Common Stock M-Exempt	Almstead Neil Gregory Chief Technical Ops Officer	Officer	24 613 Value: $970.2K
Jul 07, 2026 Sell	Common Stock S-Sale	Almstead Neil Gregory Chief Technical Ops Officer	Officer	3 956 Value: $344.8K
Jul 07, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Almstead Neil Gregory Chief Technical Ops Officer	Officer	24 613 Value: $970.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PTC THERAPEUTICS

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offer...

Read Full Profile Here